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Accumulation of amyloid-β (Aβ) within extracellular spaces of the brain is a hallmark of Alzheimer disease (AD). In sporadic, late-onset AD, there is little evidence for increased Aβ production, suggesting that
decreased elimination from the brain may contribute to elevated levels of Aβ and plaque formation. Efflux
transport of Aβ across the blood-brain barrier (BBB) contributes to Aβ removal from the brain. P-glycoprotein (Pgp) is highly expressed on the luminal surface of brain capillary endothelial cells and contributes
to the BBB. In Pgp-null mice, we show that [125I]Aβ40 and [125I]Aβ42 microinjected into the CNS clear at half
the rate that they do in WT mice. When amyloid precursor protein–transgenic (APP-transgenic) mice were
administered a Pgp inhibitor, Aβ levels within the brain interstitial fluid significantly increased within hours
of treatment. Furthermore, APP-transgenic, Pgp-null mice had increased levels of brain Aβ and enhanced Aβ
deposition compared with APP-transgenic, Pgp WT mice. These data establish a direct link between Pgp and
Aβ metabolism in vivo and suggest that Pgp activity at the BBB could affect risk for developing AD as well as
provide a novel diagnostic and therapeutic target.
*OUSPEVDUJPO
Conversion of amyloid-β (Aβ) within the extracellular spaces of
the brain into toxic soluble and insoluble forms is accelerated at
higher concentrations, implying that pathways influencing Aβ
production or elimination could potentially modulate disease
progression. Aβ is secreted from neurons into brain interstitial
fluid (ISF), where it is eliminated by proteolytic degradation (1, 2),
passive bulk flow (3), and active transport across the blood-brain
barrier (BBB) (4, 5). The latter, representing efflux across the BBB
into the periphery, appears to be a substantial pathway for elimination of CNS-derived Aβ (5). It has been demonstrated that lowdensity lipoprotein receptor–related protein (LRP1) is a major Aβ
efflux transporter at the BBB (6); however, other Aβ transporters
likely exist as well (7, 8). P-glycoprotein (Pgp; ABCB1), the 170-kD
protein product of the multidrug resistance-1 (MDR1) gene, when
overexpressed in tumor cells, confers multidrug resistance due to
efflux transport of a variety of cytotoxic agents (9). Pgp is also highly expressed on the luminal surface of brain capillary endothelial
cells, wherein Pgp functionally constitutes a major component of
the BBB by limiting CNS penetration of various chemotherapeutic
agents, small peptides, antibiotics, HIV protease inhibitors, and
antidepressant drugs (10, 11). In mice, Pgp is encoded by both
Nonstandard abbreviations used: Aβ, amyloid-β; AD, Alzheimer disease; APP,
amyloid precursor protein; BBB, blood-brain barrier; ISF, interstitial fluid; LRP1, lowdensity lipoprotein receptor–related protein 1; MDR1, multidrug resistance-1; Pgp,
P-glycoprotein; RAGE, receptor for advanced glycation endproducts.
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mdr1a and mdr1b, which have 90% sequence homology to each
other and 80% to human MDR1 (10). Thus, double-knockout mice
lacking both mdr1a and mdr1b completely eliminate Pgp activity at
the BBB. Using an inside-out membrane vesicle preparation, Lam
and colleagues provide in vitro biochemical data suggesting that
Aβ may be a substrate for Pgp transport (12). Interestingly, regionspecific levels of Aβ deposition in post-mortem Alzheimer disease
(AD) brain are inversely correlated to the level of Pgp in brain vasculature as assessed by immunohistochemistry (13). Herein, we
demonstrate using Pgp-null mice that Aβ removal from the brain
is at least partially mediated by Pgp on the BBB. Similarly, acute
inhibition of Pgp activity, using a selective Pgp inhibitor, increases
Aβ levels in brain ISF within hours of treatment. Furthermore, the
lack of Pgp expression exacerbates Aβ deposition in a mouse model
of AD. These data strongly suggest that Pgp normally transports
Aβ out of the brain and that perturbation of Aβ efflux directly
affects Aβ accumulation within the brain.
3FTVMUT
To directly assess the role of Pgp in transport of Aβ across the BBB,
we first microinjected [125I]Aβ40 or [125I]Aβ42 into the brains of
mdr1a/b–/– double-knockout (Pgp-null) mice and WT controls (7).
[14C]inulin, a reference molecule that is neither actively transported
across the BBB or retained within the brain, was coadministered to
measure bulk flow of ISF in the same mice. Thirty minutes following
coadministration of tracers, mice were sacrificed, and the content
of each compound remaining in the brain was assessed (Figure 1,
A and C). Significantly more [125I]Aβ40 and [125I]Aβ42 were retained
within the brains of Pgp-null animals compared with Pgp WT mice
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(P = 0.0123 and P = 0.0047, respectively), strongly suggesting that Aβ
elimination was hindered in these animals. Removal of [3H]leucine,
a Pgp-independent, actively transported molecule, was unaffected at 10 minutes after injection (61.4% ± 3.8% and 62.7% ± 5%
retained in Pgp WT [FVB] versus Pgp-null, respectively). Similarly,
bulk flow pathways, accounting for less than 20% of clearance,
appeared unchanged in the knockout animals as demonstrated by
nearly identical levels of inulin remaining in both groups. As shown
in Figure 1B, after passive elimination was taken into account, 31%
of injected Aβ40 was transported across the BBB in WT mice, whereas only approximately 14% was cleared in the Pgp-null animals
(P = 0.0033). Similarly, 16% of Aβ42 was transported in Pgp WT mice
compared with 6% in Pgp-null mice (Figure 1D). Compared with
Aβ40, significantly less Aβ42 was removed from the brain in WT and
Pgp-null mice, which is consistent with previous studies showing
that Aβ40 is generally actively transported across the BBB more than
Aβ42 (7). LRP1 has been previously shown to transport Aβ across
the BBB (5, 7). While overall levels of LRP1 in brain homogenates
were comparable (data not shown), interestingly, levels of LRP1
decreased by 50% in brain capillaries of 2- to 3-month-old Pgp-null
mice as compared with Pgp WT mice (Figure 1E). This decrease
in LRP1 expression at the BBB may have partially contributed to
decreased Aβ clearance in Pgp-null mice.
Next, we assessed how acute inhibition of Pgp activity affected
brain ISF Aβ levels. We utilized APPsw (also called Tg2576) mice,
which overexpress human amyloid precursor protein (APP), with
a mutation that in humans causes an autosomal dominant form
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of early-onset familial AD (14). A selective Pgp inhibitor, XR9576
(15), was used to block Pgp activity at the BBB in APPsw mice.
Because brain capillary endothelial cells transport molecules out
of the brain ISF into the periphery, we directly assessed this fluid
for changes in Aβ levels following intravenous administration
of XR9576 at 80 mg/kg, a dose that inhibits Pgp function at the
BBB, as determined by [99mTc]Sestamibi analysis (data not shown).
Using in vivo microdialysis in awake, freely moving mice (16, 17),
we first determined a basal concentration of ISF Aβ over 5 hours,
then treated mice with either vehicle or XR9576 and continued to
assess ISF Aβ levels for an additional 10 hours (Figure 2A). Eight
hours after treatment, ISF Aβ levels increased almost 30% compared with vehicle-treated mice (P < 0.05), suggesting that acute
inhibition of Pgp at the BBB caused decreased elimination of Aβ
from brain ISF. Ten hours after treatment with either vehicle or
XR9576, cerebral microvessels were also isolated and assessed for
levels of LRP1 by Western blotting. LRP1 levels in endothelial cells
did not change (Figure 2B), indicating that, in this case, the change
in ISF Aβ levels is not attributable to LRP1 downregulation but is
likely due to specific inhibition of Pgp.
Next, we determined whether the absence of Pgp at the BBB
would promote Aβ deposition. We bred APPsw+/– mice to mdr1a/b–/–
animals to produce littermate mice that were positive for the
APPsw transgene and either Pgp-null (APPsw+/–, mdr1a/b–/–) or Pgp
WT (APPsw+/–, mdr1a/b+/+). To confirm that transgenic expression
of mutated human APP did not impact basal function of Pgp in
vivo, biodistribution studies utilizing [99mTc]Sestamibi, a radio-
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pharmaceutical that has been validated as a sensitive probe of Pgp
transport function (18), were performed in 2- to 4-month-old WT
(mdr1a/b+/+) and Pgp-null (mdr1a/b–/–) mice, both in the absence
and presence of the APPsw+/– transgene. Normally, [99mTc]Sestamibi
is readily transported out of the brain by Pgp. However, in Pgp-null
animals, [99mTc]Sestamibi levels increase in the brain as it permeates cerebral capillaries and is not removed effectively. Five minutes
after intravenous bolus injection of [99mTc]Sestamibi (2 μCi), brain
content of the tracer was 0.22% ± 0.02% injected dose/g (ID/g) in
WT controls versus 0.85% ± 0.14% ID/g in Pgp-null mice (Figure 3).
There was no difference in blood content of the tracer between the
2 strains (P > 0.2). This approximately 3.5-fold increase in brain
penetration of [99mTc]Sestamibi in Pgp-null mice was consistent
with previous studies (19). In animals of similar age that expressed
the APPsw+/– transgene, brain penetration of the tracer was also
increased by approximately 3.5-fold in Pgp-null animals compared
with those expressing Pgp (Figure 3). Thus, basal activity of Pgp
was independent of the APPsw+/– transgene (P > 0.3).
When allowed to survive to 12 months, APPsw+/– mice exhibited
substantial Aβ deposition throughout the neocortex and hippocampus (Figure 4, A and B). The area covered by Aβ immunoreactivity in the hippocampus was significantly greater in APPsw,
Pgp-null animals compared with APPsw, Pgp WT littermates
(P = 0.0041; Figure 4C). The amount of fibrillar Aβ, as determined
by thioflavine S staining, was also significantly elevated in Pgpnull animals (P = 0.0276; Figure 4D). However, when the amount
of thioflavine S was normalized to total plaque load, there was
not a significant difference in the percentage of fibrillar plaques
between groups (Figure 4E). This suggests that while Pgp deletion leads to greater Aβ deposition, Pgp does not preferentially
alter the conversion of plaques into fibrillar structures. There
was no apparent change in the amount of vascular Aβ accumulation in 12-month-old Pgp-null animals; however, it remains possible that at later ages, when there is a greater amount of cerebral
amyloid angiopathy, there may be a noticeable affect. The mass
of insoluble Aβ42, as assessed by guanidine extraction and Aβ
ELISA, was 2-fold greater in the hippocampus of Pgp-null animals (P = 0.0499; Figure 4F), while there was only a trend toward
an increase in insoluble Aβ40 (P = 0.2472; Figure 4G). Carbonate-extractable Aβ40 and Aβ42 was not different between these
The Journal of Clinical Investigation

groups (data not shown). Similar to the hippocampus, there
was a trend toward elevated Aβ plaque load in the neocortex of
Pgp-null mice; however, this increase was not statistically significant (Figure 4H). These findings indicate that abrogation of the
Pgp transporter at the BBB gave rise to greater Aβ accumulation
within the brain and suggest that modulation of Pgp activity can
directly influence progression of Aβ pathology. Because genetic
deletion of Pgp also causes a decrease in the level of LRP1 at the
BBB (Figure 1), it remains possible that the changes in Aβ deposition are due to a combined decrease in both Aβ transporters.
In fact, these Aβ transporters may be playing a synergistic role,
with LRP1 functional on the basolateral surface and Pgp on the
luminal surface of brain endothelial cells.
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Pgp shares sequence homology and substantial pharmacological cross-reactivity with several members of the ATP-binding cassette superfamily of transporters that are also expressed at the
BBB, including multidrug-resistance–associated protein-1 (MRP1,
also known as ABCC1) (9). In 12-month-old APPsw, Pgp-null
(APPsw+/–, mdr1a/b–/–) mice, expression of MRP1 in hippocampal
homogenates was elevated compared with Pgp WT (APPsw+/–,
mdr1a/b+/+) mice (P = 0.0401; data not shown). Although Pgp and
MRP1 have overlapping pharmacological profiles, it is unknown
whether MRP1 can also transport Aβ in vivo. In vitro studies suggest that MRP1 cannot transport Aβ (12). Receptor for advanced
glycation endproducts (RAGE), a transporter on the BBB that is
responsible for transporting Aβ from the blood into the brain (20,
21), was expressed at similar levels in hippocampal homogenates
of 12-month-old APPsw, Pgp-null and APPsw, Pgp WT mice (data
not shown). The potential contribution of each of these transporters to Aβ clearance from the brain and how they might interact or
compensate for each other requires further investigation.
%JTDVTTJPO
Herein, we demonstrate that Pgp is involved in the transport of
Aβ across the BBB in vivo and that ablation of Pgp at the BBB
enhances Aβ deposition. While Pgp deletion has not been reported
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in humans, several mechanisms for modulation of Pgp activity at
the BBB could influence AD. Several Pgp single nucleotide polymorphisms, such as the exon 26 3435T allele, have been described
that decrease Pgp expression and result in functional differences
in oral absorption and disposition of drugs (22). It is conceivable
that similar polymorphisms in Pgp could decrease Aβ transport
out of the brain, thereby increasing the probability of plaque formation. Conversely, polymorphisms that increase Pgp transport
activity may decrease the risk of Aβ deposition and development of
AD. A detailed genetic analysis of Pgp polymorphisms in relation
to AD in humans could test this hypothesis.
In addition to the impact of genetic polymorphisms on Pgp activity, many commonly used drugs and herbal medicinals alter Pgp
function. For example, dexamethasone, morphine, rifampin, quercetin, and St. John’s wort are reported to enhance Pgp activity, while
verapamil, cyclosporine A, erythromycin, fluoxetine, progesterone,
HIV protease inhibitors, and several statins inhibit Pgp activity (for
review, see refs. 9, 23). While some of these compounds only affect
Pgp activity slightly in short-term assays, with chronic use or in
combination, it is possible that these drugs could have a greater
effect on Pgp function and, consequently, on brain Aβ levels. Since
Pgp function can be modulated pharmacologically, there is potential for drugs that enhance activity to increase Aβ clearance from
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the brain. For example, a randomized clinical trial demonstrated
that the antibiotic rifampin lessened cognitive decline in patients
with mild to moderate AD after 12 months of treatment (24). This
improvement in cognitive function did not appear to be linked to
the drug’s antibiotic activity. Because rifampin is also a Pgp substrate and inducer, the effects of rifampin on cognitive ability may
be linked to enhanced clearance of Aβ from the brain via Pgp-mediated transport. An additional advantage of modulating Pgp activity
is that because Pgp is expressed on the luminal surface of brain
capillary endothelial cells and not within the CNS per se, drugs may
not be required to cross the BBB, a typical hurdle in developing
CNS-targeted therapies. Given that a variety of genetic, therapeutic, and dietary factors can influence Pgp function, thus potentially
affecting Aβ transport, it will be interesting to determine whether
these features correlate with the incidence of AD.
.FUIPET
Animals. All experimental procedures involving animals were approved by
the Animal Studies Committee at Washington University and performed in
accordance with their guidelines. We utilized 8- to 10-week-old mdr1a/b–/–
double-knockout mice on an FVB background (Taconic) and WT controls
(also on an FVB background) for our BBB transport studies. We also bred
mdr1a/b–/– mice to APPsw+/– hemizygous mice (Tg2576 on a C57BL/6-SJL
background; a generous gift from K. Ashe, University of Minnesota, Minneapolis, Minnesota, USA). We then bred F1 offspring from this colony to
each other to produce littermate mdr1a/b homozygous (+/+) and doubleknockout (–/–) mice that were hemizygous for the APPsw+/– transgene. Animals were screened for the presence of APPsw as well as mdr1a and mdr1b
genes by PCR analysis of tail DNA. Aβ content in the brain was analyzed
when animals were 12 months old.
BBB transport. Transport of human [125I]Aβ40 [125I]Aβ42 across the BBB and
calculations were performed as previously described (4, 8). Briefly, a guide
cannula was implanted stereotaxically into the right caudate-putamen of
anesthetized mice at coordinates 0.9 mm anterior to bregma, 1.9 mm lateral, and 2.9 mm below the dura. Animals were allowed to recover after
surgery prior to radiotracer studies. The clearance experiments were performed before substantial chronic processes occurred, typically 4–6 hours
following cannula implantation, to allow the BBB to at least partially repair
and exclude large molecules (8, 16). Twelve nanomoles of [14C]inulin and
either [125I]Aβ40 or [125I]Aβ42 was coinjected in a volume of 0.5 μl over 5
minutes using an ultra micropump (World Precision Instruments Inc.).
The specific activities of peptide were in the range of 80–120 μCi/μg.
The percentage of radioactivity remaining in the brain after microinjection was determined as percentage recovery in brain = 100 × (Nb/Ni),
where Nb is the radioactivity remaining in the brain at the end of the experiment and Ni is the radioactivity microinjected into brain ISF, i.e., the disintegrations per minute for [14C]inulin and the counts per minute for trichloroacetic acid–precipitable [125I]radioactivity (intact Aβ). The percentage of Aβ
cleared through the BBB was calculated as [(1 – Nb(Aβ)/Ni(Aβ)) – (1 – Nb(inulin)/
Ni(inulin))] × 100, using a standard time of 30 minutes. D-[4,5-3H]leucine
(Amersham Biosciences) transport across the BBB was assessed using a
method similar to that described above: 750 nmol of [3H]leucine, specific
activity 1.16 Ci/mg, was injected in a volume of 0.5 μl followed by measurement of radioactivity within the brain at 10 minutes.
ISF Aβ in vivo microdialysis. In vivo microdialysis to assess brain ISF Aβ1–x in
the hippocampus of awake, freely moving 3-month-old APPsw+/– mice was
performed exactly as described previously (16, 17). Aβ1–x represents all Aβ
peptides beginning at amino acid 1 of the N-terminus with the C-terminus
being variable, but predominantly either ending at position 40 or 42. An initial 4- to 6-hour recovery period elapsed after guide implantation and probe
The Journal of Clinical Investigation

insertion to allow for tissue recovery, followed by collection of microdialysis
samples for 5 hours at 1-hour intervals at a flow rate of 1.5 μl/min to establish basal level of ISF Aβ. XR9576 (80 mg/kg body weight; Xenova QLT Inc.;
diluted in 5% dextrose) or vehicle was injected into the jugular vein, and an
additional 10 one-hour microdialysis samples were collected. Concentrations of ISF Aβ1–x for each mouse were expressed as the percentage of basal
level for each mouse (mean of 5 hours prior to treatment).
[99mTc]Sestamibi transport and biodistribution. The radiopharmaceutical
99m
[ Tc]Sestamibi (Bristol-Myers Squibb Co.) was prepared from a 1-step
commercial kit formulation by addition of [99mTc]TcO4– according to the
manufacturer’s recommendations (25). Sep-Pak purification (>95%) and
quality control of the tracer were performed as previously described (25).
Following intravenous injection, distribution of [99mTc]Sestamibi in the
brain and blood of Pgp WT and Pgp-null mice with or without coexpression
of APPsw+/– was determined 5 minutes after injection as previously described
(26, 27). Data are expressed as percent injected dose per gram tissue [(μCi
[99mTc]Sestamibi in tissue) (μCi injected [99mTc]Sestamibi)–1 (g tissue)–1 × 100)]
and are reported as mean ± SEM (n = 3–4) or ± range (n = 2).
Histological analysis. Tissue sections were cut in the coronal plane at 50 μm
on a freezing sliding microtome from the genu of the corpus callosum
through the caudal extent of the hippocampus. The percent surface area
covered by Aβ-immunoreactivity deposits (% Aβ load), as identified with
a mouse monoclonal antibody against the N terminus of human Aβ,
m3D6 (Eli Lilly and Co.), was quantified following unbiased stereological
principles as described (28). Thioflavine S staining was performed stereologically and quantified as previously described (29). Aβ and thioflavine S
load were determined in the cingulate cortex and hippocampus in 3 brain
sections, each separated by 300 μm.
Aβ quantification. Aβ40 and Aβ42 levels in brain tissue were determined
by sandwich ELISA as previously described (16). Briefly, m266, m2G3, or
m21F12 were used as coating antibodies to capture Aβ1–x, Aβ40, or Aβ42,
respectively. Biotinylated m3D6, a human-specific antibody against the
N terminus of Aβ, was used as the reporting antibody in each ELISA. To
evaluate the carbonate-soluble and -insoluble pools of Aβ in brain tissue,
we performed a carbonate extraction (100 mM carbonate, 50 mM NaCl,
protease inhibitors, pH 11.5) of hippocampal tissue (1:10, wt/vol) on ice
followed by a 5 M guanidine, pH 8.0 extraction for 3 hours at room temp.
Tissue samples were dounce homogenized and spun in a microcentrifuge
at 21,000 g for 15 minutes at 4°C following each extraction.
Western blotting. Hippocampal tissue from 12-month-old APPsw, Pgp WT,
and APPsw, Pgp-null littermates was homogenized in 150 mM NaCl, 50 mM
Tris pH 7.4, 0.5% deoxycholic acid, 0.1% SDS, 1% Triton X-100, 2.5 mM EDTA,
and protease inhibitors. Western blotting for MRP1, LRP1, and RAGE were
performed using 3–8% NuPAGE Tris-Acetate gels (Invitrogen Corp.) with 30 μg
of protein loaded per lane. Cerebral microvessels from 2- to 3-month-old Pgp
WT (FVB) and Pgp-null mice were isolated as described (30). Microvessels
were homogenized in cold lysis buffer: 150 mM NaCl, 50 mM Tris pH 7.4,
0.1% SDS, 1% Triton X-100, and complete protease inhibitor cocktail (Roche
Diagnostics Corp.). Individual protein homogenates were separated under
nonreducing conditions, transferred to nitrocellulose membrane, and probed
with rabbit anti–LRP1-85 (LRP, β-chain specific; EMD Biosciences Inc.), rabbit anti-RAGE (Santa Cruz Biotechnology Inc.), or rat anti-MRP1 (Signet Laboratories), followed by goat anti-rabbit or donkey anti-rat secondary antibodies conjugated to HRP (Jackson ImmunoResearch Laboratories Inc.). Mouse
anti-tubulin (Sigma-Aldrich) or anti–β-actin (Santa Cruz Biotechnology Inc.)
were used to detect control proteins in each lane. Bands were detected with
Lumigen-TMA6 (Amersham Biosciences) and captured digitally using Kodak
ImageStation 440CF. The relative absorbance of each band was detected by
densitometry and normalized to protein loaded in each lane. Analysis was
performed using Kodak 1D Image Analysis software version 3.6.
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Statistics. Data shown in figures represent mean ± SEM. Mann-Whitney
U test was used to compare data between Pgp-null and WT mice, as well as
LRP1 expression levels in endothelial cells of XR9576 and vehicle-treated
mice. ISF Aβ levels in XR9576 and vehicle-treated mice, over the duration
of the experiment, were compared by 2-way ANOVA followed by the Bonferroni post-hoc test to compare means. P values of less than 0.05 were considered statistically significant. All statistical analyses were performed using
Prism version 4.02 (GraphPad Software) for Windows (Microsoft Corp.).
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